AI Article Synopsis
- EGFR T790M mutations are common resistance mechanisms against early tyrosine kinase inhibitors, but osimertinib typically offers effective treatment for such cases.
- A 68-year-old woman with lung adenocarcinoma and multiple mutations, including T790M, did not respond to osimertinib.
- The case indicates that osimertinib might be less effective for patients with rare mutations like G719S, particularly when combined with T790M resistance.
Article Abstract
Epidermal growth factor receptor (EGFR) T790M mutations are the most frequent mechanism of resistance to first- and second-generation tyrosine kinase inhibitors, and osimertinib is an effective treatment for patients with both EGFR-activating mutations and T790M resistance mutations. We describe the case of a 68-year-old woman with lung adenocarcinoma with G719S, S768I, and T790M mutations in which osimertinib treatment was unsuccessful. The patient died of disease progression one month after discontinuing osimertinib treatment. This case suggests that osimertinib may be ineffective for treating patients with uncommon mutations such as G719S when the patient has also acquired a T790M resistance mutation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355418 | PMC |
| http://dx.doi.org/10.2169/internalmedicine.0923-18 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!